← back to search

Martin Uhl

Friedrich-Alexander-Universität Erlangen-Nürnberg · DE
Area of research
Genetics · Pulmonary and Respiratory Medicine
Research interest
Research interests include Glioma Diagnosis and Treatment, Brain Metastases and Treatment, TGF-β signaling in diseases, and Metabolism, Diabetes, and Cancer.
h-index
16
citations
3,855
works
47
NIH funding
primary concept
email

Recent publications

Metabolic Heterogeneity of Brain Tumor Cells of Proneural and Mesenchymal Origin
International Journal of Molecular Sciences 2022cited by 13position: middledoi
Metabolic Heterogeneity of Brain Tumor Cells of Proneural and Mesenchymal Origin
Research Square 2020cited by 1position: middledoi
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
The Lancet 2019cited by 572position: middledoi
Early postoperative tumor progression predicts clinical outcome in glioblastoma—implication for clinical trials
Journal of Neuro-Oncology 2017cited by 30position: lastdoi
ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial
Neuro-Oncology 2017cited by 22position: middledoi
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma
Neuro-Oncology 2017cited by 21position: middledoi
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O<sup>6</sup>-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
Journal of Clinical Oncology 2016cited by 196position: middledoi
Metformin inhibits proliferation and migration of glioblastoma cells independently of TGF-β2
Cell Cycle 2016cited by 43position: middledoi
Fatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroacetate and Artesunate in a Glioblastoma Multiforme Patient: Case Report and Review of the Literature
Frontiers in Oncology 2016cited by 27position: firstdoi
Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma.
PubMed 2016cited by 18position: last
Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab
Journal of Neuro-Oncology 2015cited by 7position: middledoi
Use of cardiac glycosides and risk of glioma
Journal of Neuro-Oncology 2015cited by 2position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Peter Hau · University Hospital Regensburg7 papers (2015–2022)Corinna Seliger · Universitätsklinikum Knappschaftskrankenhaus Bochum6 papers (2015–2022)Markus J. Riemenschneider · University Hospital Regensburg4 papers (2015–2022)Arabel Vollmann‐Zwerenz · University of Regensburg4 papers (2016–2022)Kathrin Renner · University of Regensburg3 papers (2016–2022)Marina Kreutz · University of Regensburg3 papers (2016–2022) · 3 papers (2016–2022)Martin Proescholdt · University of Regensburg3 papers (2016–2022)Birgit Jachnik · University of Regensburg3 papers (2016–2022)Verena Leidgens · University of Regensburg3 papers (2016–2022)Katja Dettmer · University of Regensburg3 papers (2016–2022)Peter J. Oefner · University of Regensburg3 papers (2016–2022)Lisa Rauer · Heidelberg University3 papers (2016–2022)Judith Proske · University of Regensburg3 papers (2016–2022)Anne-Louise Meyer · University of Regensburg3 papers (2016–2022) · 2 papers (2020–2022)Elisabeth Bumes · University of Regensburg2 papers (2015–2016)Leon D. Kaulen · German Cancer Research Center2 papers (2020–2022)Markus Hutterer · Ordensklinikum Linz Barmherzige Schwestern2 papers (2015–2016)Nils Ole Schmidt · University Hospital Regensburg2 papers (2020–2022)